Determining the contribution of Streptococcus pneumoniae to community-acquired pneumonia in Australia

J Kevin Yin, Sanjay H Jayasinghe, Patrick G Charles, Catherine King, Clayton K Chiu, Robert I Menzies and Peter B McIntyre
Med J Aust 2017; 207 (9): . || doi: 10.5694/mja16.01102
Published online: 6 November 2017


Objective: To evaluate trends in the proportion and severity of community-acquired pneumonia (CAP) attributable to Streptococcus pneumoniae (pneumococcus) in Australians aged 18 years and over.

Study design: Systematic review with unpublished data from the largest study.

Data sources: Multiple key bibliographic databases to June 2016.

Study selection: Australian studies on the aetiology of CAP in adults.

Data synthesis: In the 12 studies identified, pneumococcus was the most common cause of CAP. Four studies were assessed as being of good quality. Participants in two studies were predominantly non-Indigenous (n = 991); the proportion of pneumococcal CAP cases declined from 26.4% in 1987–88 to 13.9% in 2004–06, and the proportion with bacteraemia decreased from 7.8% to 3.8%. In two studies with predominantly Indigenous participants (n = 252), the proportion with pneumococcal bacteraemia declined from 6.8% in 1999–2000 to 4.2% in 2006–07. In the largest study (n = 885; 2004–06), 50.8% (60/118) of pneumococcal CAP occurred in people who were ≥ 65 years old. Among patients aged ≥ 65 years, intensive care unit admission and death were more common in patients who were ≥ 85 years old compared with younger patients (12.5% v 6.8%; 18.8% v 6.8% respectively), and also more common in the 19 patients with bacteraemia than in those without it (15.8% v 2.6%; 10.5% v 7.9% respectively). Of 17 cases of bacteraemia serotyped, 12 were due to 13-valent pneumococcal conjugate vaccine (13vPCV) serotypes and three to additional serotypes in 23-valent pneumococcal polysaccharide vaccine (23vPPV).

Conclusions: Available data suggest that the proportion of CAP attributable to pneumococcus (both bacteraemic and non-bacteraemic) has been declining in Australian adults. Should 13vPCV replace the 23vPPV currently funded by the National Immunisation Program for persons aged ≥ 65 years, surveillance to track non-bacteraemic pneumococcal CAP will be essential to evaluate the impact.

  • J Kevin Yin1,2
  • Sanjay H Jayasinghe1,2
  • Patrick G Charles3
  • Catherine King1
  • Clayton K Chiu1
  • Robert I Menzies4
  • Peter B McIntyre1

  • 1 National Centre for Immunisation Research and Surveillance, Kids Research Institute, Children's Hospital at Westmead, Sydney, NSW
  • 2 University of Sydney, Sydney, NSW
  • 3 Austin Health, Melbourne, VIC
  • 4 University of New South Wales, Sydney, NSW



The Australian Government Department of Health supported the National Centre for Immunisation Research and Surveillance (NCIRS) of vaccine preventable diseases in Australia. However, the views expressed are not necessarily those of the department. The study was undertaken as part of the regular policy deliberations of the Australian Technical Advisory Group on Immunisation. We thank the members of the Australian Community-acquired Pneumonia Study Collaboration.

Competing interests:

Since the completion of this study and the submission of the manuscript for publication, J Kevin Yin left his employment at the NCIRS to work for Sanofi Pasteur Australia and New Zealand.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.